Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin Sells 51,504 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tempus AI Stock Performance

TEM stock traded down $0.99 during midday trading on Friday, hitting $41.00. The company’s stock had a trading volume of 5,041,241 shares, compared to its average volume of 1,427,998. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $79.49. The firm has a 50-day moving average of $52.88. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Wall Street Analyst Weigh In

Several research firms have weighed in on TEM. Guggenheim began coverage on shares of Tempus AI in a report on Monday. They issued a “buy” rating and a $74.00 target price on the stock. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Wolfe Research initiated coverage on Tempus AI in a research note on Friday. They set an “outperform” rating and a $60.00 target price for the company. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, Loop Capital raised their price objective on Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Institutional Investors Weigh In On Tempus AI

Large investors have recently bought and sold shares of the stock. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the 3rd quarter worth about $30,000. Geode Capital Management LLC grew its position in shares of Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the last quarter. Vestor Capital LLC purchased a new stake in shares of Tempus AI in the 3rd quarter valued at about $153,000. The Manufacturers Life Insurance Company lifted its stake in Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after buying an additional 2,765 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in Tempus AI during the 3rd quarter worth $218,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.